![]() |
市場調查報告書
商品編碼
1827706
2025年全球骨骼生長刺激器市場報告Bone Growth Stimulator Global Market Report 2025 |
近年來,骨骼生長刺激器市場規模強勁成長,從2024年的16.5億美元增加到2025年的18億美元,複合年成長率達9.2%。預測期內的成長歸因於人口老化、整形外科疾病盛行率上升、人們對非侵入性治療的認知不斷提高、醫療保健可及性的擴大、報銷政策的優惠、對微創解決方案的需求不斷成長以及整形外科手術的普及率不斷提高。
預計未來幾年骨骼生長刺激器市場規模將快速成長,到2029年將達到26.5億美元,複合年成長率為10.1%。預測期內的成長可歸因於社會意識的提高、再生醫學的普及、醫療基礎設施的投資、用途和適應症的拓展以及支持性醫療政策。預測期內的主要趨勢包括再生醫學、3D列印技術的使用、無線和物聯網技術在遠端患者監護的應用、以患者為中心的護理以及遠端醫療應用的日益普及。
骨骼生長刺激器 (BGS) 是一種旨在促進骨折後骨骼自然癒合的裝置。 BGS 的主要作用是將能量輸送到癒合中的骨骼表面,這可以透過脈衝電磁場或超音波技術實現。在脈衝電磁場中,BGS 會吸引帶相反電荷的骨端,刺激新骨生長和融合,最終加速癒合過程。骨骼生長刺激器透過向骨折或癒合部位施加超音波或電流來輔助難以癒合的骨骼癒合。
骨骼生長刺激器 (BGS) 的主要類型包括骨生長刺激器、骨形態蛋白 (BMP) 和富血小板血漿療法。骨生長刺激器可以植入體內,也可以透過綁帶進行外部固定,從而加快骨折癒合速度並縮短癒合時間。這些裝置可用於治療骨折、脊椎融合、骨形成、關節重建和椎間滑脫。 BGS 的主要終端使用者包括醫院、門診手術中心 (ASC)、專科診所和居家醫療。
2025年春季美國大幅提高關稅及其引發的貿易摩擦對醫療設備產業產生了重大影響,尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價,製造商面臨利潤壓力。監管挑戰使情況更加複雜,因為由於關稅而更換供應商通常需要重新認證醫療設備,導致市場進入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快研發更具成本效益的材料來降低風險。
本研究報告是商業研究公司(The Business Research Company)新報告系列的一部分,該系列提供骨骼生長刺激器市場統計數據,包括全球市場規模、各地區市場佔有率、競爭對手的骨骼生長刺激器市場佔有率、詳細的骨骼生長刺激器細分市場、市場趨勢和機遇,以及在骨骼生長刺激器行業取得成功所需的其他數據。這份骨骼生長刺激器市場研究報告對該行業的現狀和未來趨勢進行了詳細分析,提供了所有必要的完整觀點。
未來五年的預測成長率為10.1%,較我們先前對該市場的預測略有下降0.1%。下降主要源自於美國與其他國家之間關稅的影響。這可能會直接影響美國,因為美國對來自德國和以色列等關鍵地區的脈衝電磁場發生器和生物相容性電極陣列徵收關稅,從而導致骨折患者的治療成本上升,非侵入性治療工具的供應減少。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響,這種影響也將更加廣泛地顯現。
骨骼生長刺激器市場預計將經歷顯著成長,主要原因是骨折發生率的上升。老齡化、飲食和慢性疾病等因素會削弱骨骼,使其更容易骨折。過度使用和重複性運動也會導致骨折。 2022 年 5 月,美國生技公司安進 (Amgen) 報告稱,骨質疏鬆症每年在美國導致約 150 萬人骨折,相關費用達 190 億美元。此外,預計從 2018 年到 2040 年,骨質疏鬆性骨折的數量每年將增加 68%,達到 320 萬人。骨折發生率的上升預計將成為推動骨骼生長刺激器市場成長的主要因素。
運動傷害的增加也推動了骨骼生長刺激器市場的成長。運動傷害會影響身體的各個部位,包括骨骼、肌肉、韌帶和肌腱,通常需要介入以促進骨骼修復和復原。骨骼生長刺激器在促進骨骼修復、組織生長和運動傷害的整體癒合方面發揮關鍵作用。美國國家安全委員會於2022年報告稱,2021年運動和休閒傷害將增加20%,2022年將再增加12%。運動傷害的增加趨勢正在推動骨骼生長刺激器市場的擴張。
技術進步是骨骼生長刺激器市場的一大趨勢,電骨生長刺激 (EBGS) 等創新方法日益受到關注。這種獨特的方法旨在促進癒合並提高癒合成功率。 EBGS 設備的廣泛採用和不斷成長的經驗已導致刺激範例和臨床結果取得重大進展。例如,2022 年 5 月,美國脊椎、整形外科和骨骼發育解決方案製造商 Orthofix Medical Inc. 的 AccelStim 骨癒合治療 III 類設備獲得了美國食品藥物管理局(FDA) 的上市前核准。 AccelStim 設備利用低強度脈衝超音波(LIPUS),為新骨折和癒合骨折(不癒合)提供了一種非手術治療選擇,並促進骨骼的自然癒合過程。
骨骼生長刺激器市場的主要企業正在優先考慮創新產品的核准,正如 ActaStim-S 脊椎融合骨骼生長刺激器系統的專利核准所示。該系統是一種非侵入性設備,旨在刺激脊椎融合手術後的骨骼修復和融合。顯著特點包括無線設計和方便用戶使用的行動應用程式。它已獲得美國食品藥物管理局(FDA) 的核准,可用於脊椎融合手術後使用或治療先前手術失敗的融合。 2022 年 8 月,美國製藥和生物技術公司 TheraGen 宣布已成功獲得其突破性 ActaStim-S脊椎融合系統的美國專利。 ActaStim-S 是一種突破性的脊椎融合刺激器,它將臨床驗證的治療刺激與現代設計和數據豐富的數位健康平台相結合。這種方法不僅可以加速癒合過程,還可以在關鍵的術後融合階段促進患者的依從性、參與度以及與醫療保健專業人員的知情溝通。
2022年11月,總部位於瑞典、生產先進不銹鋼和特種合金等高附加價值產品的製造商Alleima收購了ENDOSMART醫療技術有限公司(ENDOSMART Gesellschaft fur Medizintechnik mbH),收購金額未揭露。此次收購旨在鞏固Alleima的市場地位,拓寬其產品範圍,並增強其在高性能材料方面的能力。 ENDOSMART醫療技術有限公司是一家專門生產醫療設備和零件的德國公司。
骨骼生長刺激器市場的主要企業包括 Arthrex Inc.、DJO Global Inc.、Stryker Corporation、Bioventus LLC、Zimmer Biomet Holdings Inc.、3M Company、Becton Dickinson and Company、Cognionics Inc.、ConMed Corporation、The Cooper Companies Inc.、DycorpMedix、Koninklijke Corporation Philips. Inc.、Ossatec Benelux BV、BTT Health GmbH、Stimulate Health Inc.、ZimVie Inc.、Enovis Inc.、DePuy Synthes Inc.、Smith & Nephew plc、BioTek Instruments Inc.、BioMimetic Therapeutics Inc、Cerament、Cook日 Inc. AG、NuVasive Inc. OrthoPediatrics Corp.、RTI Surgical Holdings Inc. 和 Wright Medical Group NV。
2024年,北美是骨骼生長刺激器市場最大的地區。預計亞太地區將成為預測期內成長最快的地區。骨骼生長刺激器市場報告涵蓋的地區包括亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。
骨骼生長刺激器市場報告涉及的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國和美國。
骨骼生長刺激器市場涵蓋電動和超音波骨骼生長刺激器的銷售。該市場的價值指的是“出廠價”,即產品製造商或生產商銷售給其他營業單位(包括下游製造商、批發商、經銷商和零售商)或直接銷售給最終客戶的商品價值。該市場中的商品價值還包括產品製造商提供的任何相關服務。
A bone growth stimulator (BGS) is a device designed to enhance the natural fusion of bones following a fracture. The primary goal of BGS is to deliver increased energy to the healing bone surface, achieved through either pulsed electromagnetic or ultrasound methods. In the case of pulsed electromagnetic fields, the BGS attracts the oppositely charged ends of the bones, stimulating new bone growth and fusion, ultimately promoting the healing process. Bone growth stimulators are employed to aid in bone healing for challenging fractures or fusions by applying ultrasonic or electrical current to the fracture or fusion site.
The main types of bone growth stimulators (BGS) include bone growth stimulation devices, bone morphogenetic proteins (BMP), and platelet-rich plasma (PRP) therapy. Bone growth stimulation devices can be either implanted internally or worn externally using straps to secure them in place, enhancing the rate and shortening the time required for fracture healing. These devices find application in the treatment of fractures, spinal fusion, osteogenesis, arthrodesis treatment, and spondylolisthesis. The primary end-use sectors for BGS include hospitals and ambulatory surgical centers (ASCs), specialty clinics, and home care.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The bone growth stimulators market research report is one of a series of new reports from The Business Research Company that provides bone growth stimulators market statistics, including bone growth stimulators industry global market size, regional shares, competitors with a bone growth stimulators market share, detailed bone growth stimulators market segments, market trends and opportunities, and any further data you may need to thrive in the bone growth stimulators industry. This bone growth stimulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bone growth stimulator market size has grown strongly in recent years. It will grow from $1.65 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to aging population and orthopedic conditions, increasing awareness of non-invasive treatments, expansion of healthcare access, favorable reimbursement policies, increased demand for minimally invasive solutions, and increased orthopedic surgery prevalence.
The bone growth stimulator market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to enhanced public awareness, regenerative medicine adoption, healthcare infrastructure investments, expanding applications and indications, and supportive healthcare policies. Major trends in the forecast period include regenerative medicine, the use of 3D printing technology, incorporating wireless and iot technologies for remote patient monitoring, patient-centric care, and increasing utilization of telemedicine.
The forecast of 10.1% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on pulsed electromagnetic field generators and biocompatible electrode arrays, sourced from key regions such as Germany and Israel, which could lead to higher treatment costs for fracture patients and reduced availability of non-invasive healing devices.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The bone growth stimulators market is expected to experience significant growth, primarily driven by the increasing number of bone fractures. Factors such as age, dietary habits, and chronic disorders can weaken bones, making them more susceptible to fractures. Overuse or repetitive motions can also contribute to bone fractures. In May 2022, Amgen, a U.S.-based biotechnology company, reported that osteoporosis leads to approximately 1.5 million fractures annually in the United States, resulting in associated expenses of $19 billion. Furthermore, it is projected that the number of osteoporotic fractures will increase by 68% annually from 2018 to 2040, reaching 3.2 million. The rising incidence of bone fractures is expected to be a significant driver for the growth of the bone growth stimulator market.
The growth of the bone growth stimulator market is also propelled by the increasing number of sports injuries. Sports injuries, which can affect various parts of the body, including bones, muscles, ligaments, and tendons, often require interventions to aid in bone repair and rehabilitation. Bone growth stimulators play a crucial role in promoting bone restoration, tissue growth, and overall healing in sports injuries. In 2022, the National Safety Council reported a 20% increase in sports and leisure injuries in 2021 and an additional 12% increase in 2022. The growing prevalence of sports injuries is contributing to the expansion of the bone growth stimulator market.
Technological advancement is a notable trend in the bone growth stimulators market, with a focus on innovative approaches such as Electrical Bone Growth Stimulation (EBGS). This unique method aims to accelerate healing and enhance fusion success rates. The increased adoption and experience with EBGS devices have led to significant advancements in stimulation paradigms and clinical outcomes. For example, in May 2022, Orthofix Medical Inc., a U.S.-based manufacturer of spinal, orthopedic, and bone development solutions, received pre-market approval from the U.S. Food and Drug Administration (FDA) for the AccelStim bone healing therapy Class III device. The AccelStim device, utilizing Low-Intensity Pulsed Ultrasound (LIPUS), provides a nonsurgical therapy option for new fractures and fractures that are still healing (nonunions), enhancing the natural healing process of the bone.
Leading companies in the bone growth stimulator market are prioritizing innovative product approvals, as evidenced by the patent approval of the ActaStim-S Spine Fusion Bone Growth Stimulator system. This system is a non-invasive device designed to stimulate bone repair and fusion following spinal fusion surgery. Notable features include a cordless design and a user-friendly mobile app. It has received approval from the U.S. Food and Drug Administration (FDA) for use after spinal fusion procedures or to treat a failed fusion from a previous operation. In August 2022, Theragen, Inc., a U.S.-based pharmaceutical and biotechnology company, announced the successful acquisition of a U.S. patent for its groundbreaking ActaStim-S Spine Fusion Bone Growth Stimulator system. ActaStim-S is a revolutionary spine fusion stimulator, incorporating clinically proven therapeutic stimulation with modern design and a data-rich digital health platform. This approach not only enhances the healing process but also promotes patient compliance, engagement, and informed communication with healthcare practitioners during the crucial post-operative fusion phase.
In November 2022, Alleima, a company based in Sweden that produces high-value-added products in advanced stainless steels and specialty alloys, acquired ENDOSMART Gesellschaft fur Medizintechnik mbH for an undisclosed amount. This acquisition is intended to bolster Alleima's market position, broaden its product range, and enhance its capabilities in high-performance materials. ENDOSMART Gesellschaft fur Medizintechnik mbH is a German company specializing in the manufacture of medical devices and components.
Major companies operating in the bone growth stimulator market include Arthrex Inc., DJO Global Inc., Stryker Corporation, Bioventus LLC, Zimmer Biomet Holdings Inc., 3M Company, Becton Dickinson and Company, Cognionics Inc., ConMed Corporation, The Cooper Companies Inc., DyMedix Corporation, Koninklijke Philips N.V., Medtronic plc, Natus Medical Incorporated, Terumo Corporation, Orthofix Medical Inc., Ossatec Benelux BV, BTT Health GmbH, Stimulate Health Inc., ZimVie Inc., Enovis Inc., DePuy Synthes Inc., Smith & Nephew plc, BioTek Instruments Inc., BioMimetic Therapeutics Inc., Cerament, Cook Medical LLC, Curasan AG, Exactech Inc., Globus Medical Inc., Integra LifeSciences Corporation, Medartis AG, NuVasive Inc., OrthoPediatrics Corp., RTI Surgical Holdings Inc., Wright Medical Group N.V.
North America was the largest region in the bone growth stimulator market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bone growth stimulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the bone growth stimulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The bone growth stimulator market consists of sales of electrical and ultrasound bone growth stimulator. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bone Growth Stimulator Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on bone growth stimulator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bone growth stimulator ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bone growth stimulator market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.